Published in Gene Therapy Weekly, May 20th, 1996
In previous research, L. Chen et al. from Harvard Medical School had shown that systemic administration of IL-12 could cure a percentage of mice burdened with the poorly immunogenic MB49 bladder cancer at the maximally tolerated dose. The cured mice were also capable of resisting rechallenge to the parental tumor in an IL-12 dose-dependent manner.
Building on these earlier experiments, colleague Stephen K. Clinton presented conclusions from a recent study at the 87th Annual Meeting of the American Association for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.